«NIH Knowledge Portal for Diabetes Researchers and General Public»: الفرق بين المراجعتين
(أنشأ الصفحة ب' هذه الأداة المعرفية Knowledge tool مثلها مثل العديد من الأدوات المعرفية الأخرى تعتبر حديثة النشوء...') |
|||
| سطر 14: | سطر 14: | ||
**The portal results from the Accelerating Medicines Partnership (AMP) for type 2 diabetes '''seeks to advance the research and treatment''' of the disorder. | **The portal results from the Accelerating Medicines Partnership (AMP) for type 2 diabetes '''seeks to advance the research and treatment''' of the disorder. | ||
***The National Institutes of Health (NIH), 10 biopharmaceutical companies, and multiple non-profit organizations launched an '''unprecedented new public-private partnership''' in February 2014. Managed through the Foundation for the NIH (FNIH), the Accelerating Medicines Partnership (AMP) '''brings''' high-level government, industry, and non-profit foundation partners '''together''' to '''identify and validate the most promising''' biological '''targets''' for therapeutics . The partners have designed a '''bold milestone-driven research plan''' to tackle this challenge for type 2 diabetes, as well as for Alzheimer’s disease and the autoimmune disorders rheumatoid arthritis and systemic lupus erythematosus (lupus). What makes this '''public-private partnership unique''' is that AMP '''data will be considered precompetitive and made publicly accessible''' to the broad biomedical community for further research. This fact sheet addresses the AMP research plan for type 2 diabetes.<ref>http://www.nih.gov/science/amp/type2diabetes.htm</ref> | ***The National Institutes of Health (NIH), 10 biopharmaceutical companies, and multiple non-profit organizations launched an '''unprecedented new public-private partnership''' in February 2014. Managed through the Foundation for the NIH (FNIH), the Accelerating Medicines Partnership (AMP) '''brings''' high-level government, industry, and non-profit foundation partners '''together''' to '''identify and validate the most promising''' biological '''targets''' for therapeutics . The partners have designed a '''bold milestone-driven research plan''' to tackle this challenge for type 2 diabetes, as well as for Alzheimer’s disease and the autoimmune disorders rheumatoid arthritis and systemic lupus erythematosus (lupus). What makes this '''public-private partnership unique''' is that AMP '''data will be considered precompetitive and made publicly accessible''' to the broad biomedical community for further research. This fact sheet addresses the AMP research plan for type 2 diabetes.<ref>http://www.nih.gov/science/amp/type2diabetes.htm</ref> | ||
| + | |||
| + | |||
| + | ==مراجع== | ||
| + | {reflist} | ||
[[تصنيف: لماذا ويكيتعمر]] | [[تصنيف: لماذا ويكيتعمر]] | ||
مراجعة 08:35، 17 أكتوبر 2015
هذه الأداة المعرفية Knowledge tool مثلها مثل العديد من الأدوات المعرفية الأخرى تعتبر حديثة النشوء وفي تطور وديناميكية مستمرة. والدليل على ذلك إختلاف عنونتها في الصفحات المختلفة وإختلاف وصفها.
لكن يبقى شئ مهم هو إهتمام هيئة خدمية هامة مثل الNIH وشركائها بإنشاء هذه الأداة المعرفية لإدراكها أهمية مساهمتها في علاج مرض رهيب إنتشر كالوباء وهو مرض السكري.
أمثلة لإختلاف العنونة والوصف:
- NIH Knowledge Portal for Diabetes Researchers and General Public[1]
- NIH Knowledge Portal for Diabetes Researchers and General Public
- Online library on genetic and clinical data concerning diabetes type 2 is available
- newly launched online library, known as knowledge portal, that permits open-access searching of clinical information and human genetic data on type 2 diabetes.
- The portal incorporates data from many global networks, gathered through decades of investigation.
- The portal results from the Accelerating Medicines Partnership (AMP) for type 2 diabetes seeks to advance the research and treatment of the disorder.
- The National Institutes of Health (NIH), 10 biopharmaceutical companies, and multiple non-profit organizations launched an unprecedented new public-private partnership in February 2014. Managed through the Foundation for the NIH (FNIH), the Accelerating Medicines Partnership (AMP) brings high-level government, industry, and non-profit foundation partners together to identify and validate the most promising biological targets for therapeutics . The partners have designed a bold milestone-driven research plan to tackle this challenge for type 2 diabetes, as well as for Alzheimer’s disease and the autoimmune disorders rheumatoid arthritis and systemic lupus erythematosus (lupus). What makes this public-private partnership unique is that AMP data will be considered precompetitive and made publicly accessible to the broad biomedical community for further research. This fact sheet addresses the AMP research plan for type 2 diabetes.[2]
مراجع
{reflist}
